Cardinal Health, Inc.는 미국, 캐나다, 유럽, 아시아 및 기타 국제 시장에 이르기까지 범위를 두고, 의료 서비스와 제품을 글로벌 규모로 통합 제공하는 기업으로 ...
Cardinal Health(CAH)는 지난 5년 동안 주가가 크게 상승하며 365.1%의 수익을 냈고, 그중 지난해에는 46.0%를 기록했습니다. 강한 실적과 자회사인 전문 헬스케어 사업에 대한 최근의 기대감에도 불구하고, 해당 주식은 업종 평균 24.9x 대비 P/E 35.2x로 평가되어 과대평가된 것으로 보입니다. 공정 P/E는 29.2x입니다. 이는 현재 주가가 향후 실행에 대한 높은 기대를 이미 반영하고 있어, 경쟁 및 규제 압력에 비해 오차 범위가 좁아졌음을 시사합니다.
Elevance Health, Inc. (ELV)는 2026년 7월 15일 2분기 2026 실적을 발표할 예정이며, Zacks 애널리스트들은 전년 대비 이익과 매출이 모두 감소할 것으로 전망하고 있습니다. 회사는 Health Benefits 부문 영업이익의 약화와 Commercial Individual 및 Medicaid의 가입자 감소로 인한 잠재적 역풍에 직면해 있으며, 강한 과거 서프라이즈 평균에도 불구하고 실적이 기대를 상회할지는 불확실합니다. 이 기사에서는 또한 다른 의료 부문 기업인 ProMIS Neurosciences, Alcon Inc., Cardinal Health, Inc.도 실적이 기대치를 상회할 것으로 예상된다고 언급합니다.
최근 한 워싱턴 출신 국회의원이 McKesson(MCK) 주식을 매입한 사실이 공개되면서, 시장 변동성과 회사의 과거 오피오이드(아편유사제) 합의에 관한 역사적 논의가 다시 주목을 받았습니다. McKesson은 최근 주가 강세를 보였고, 소셜미디어에서는 시장 성과와 거래량 패턴을 중심으로 논의가 이뤄지고 있습니다. 내부자 매도는 매수보다 크게 앞서고 있으며, 기관 투자자들은 엇갈린 활동을 보이고 있고 애널리스트들은 MCK에 대해 높은 목표주가를 제시했습니다.
Vectus Biosystems Limited는 선도 후보물질 VB0004(특발성 폐섬유증을 표적)를 위한 FDA 제출 절차를 지원하기 위해 미국 규제 대리인으로 Cardinal Health Regulatory Services를 지정했습니다. 이번 전략적 파트너십은 희귀의약품 지정(Orphan Drug Designation)과 IND(임상시험용 신약) 신청을 포함해 미국에서 명확한 규제 경로를 확립하는 것을 목표로 합니다. 투자자들은 해당 회사의 향후 개발과 시장 잠재력에 있어 특히 VB0004와 관련해 규제 진행 상황을 면밀히 모니터링할 것입니다. VB0004는 유리한 안전성 프로파일로 Phase Ia 임상 연구를 완료했습니다.
카디널 헬스의 주가는 미국의 주요 헬스케어 의약품 및 의료용품 유통업체로서 다각화된 역할을 수행하는 덕분에 안정적으로 유지되고 있습니다. 반복적인 유통 물량과 덜 경기순환적인 헬스케어 수요에 의해 뒷받침되는 회사의 방어적(디펜시브) 특성은 헬스케어 공급망에 대한 노출을 원하는 투자자들에게 매력적으로 작용합니다. 이 회사의 비즈니스 모델은 규모, 운영 효율성, 가격 및 규제 리스크 같은 다양한 요인의 관리가 성과를 내는 한편, 고령화 같은 장기적인 헬스케어 트렌드의 혜택도 누립니다.
Cardinal Health(CAH)는 지난 5년 동안 주가가 크게 상승하며 365.1%의 수익을 냈고, 그중 지난해에는 46.0%를 기록했습니다. 강한 실적과 자회사인 전문 헬스케어 사업에 대한 최근의 기대감에도 불구하고, 해당 주식은 업종 평균 24.9x 대비 P/E 35.2x로 평가되어 과대평가된 것으로 보입니다. 공정 P/E는 29.2x입니다. 이는 현재 주가가 향후 실행에 대한 높은 기대를 이미 반영하고 있어, 경쟁 및 규제 압력에 비해 오차 범위가 좁아졌음을 시사합니다.
Elevance Health, Inc. (ELV)는 2026년 7월 15일 2분기 2026 실적을 발표할 예정이며, Zacks 애널리스트들은 전년 대비 이익과 매출이 모두 감소할 것으로 전망하고 있습니다. 회사는 Health Benefits 부문 영업이익의 약화와 Commercial Individual 및 Medicaid의 가입자 감소로 인한 잠재적 역풍에 직면해 있으며, 강한 과거 서프라이즈 평균에도 불구하고 실적이 기대를 상회할지는 불확실합니다. 이 기사에서는 또한 다른 의료 부문 기업인 ProMIS Neurosciences, Alcon Inc., Cardinal Health, Inc.도 실적이 기대치를 상회할 것으로 예상된다고 언급합니다.
최근 한 워싱턴 출신 국회의원이 McKesson(MCK) 주식을 매입한 사실이 공개되면서, 시장 변동성과 회사의 과거 오피오이드(아편유사제) 합의에 관한 역사적 논의가 다시 주목을 받았습니다. McKesson은 최근 주가 강세를 보였고, 소셜미디어에서는 시장 성과와 거래량 패턴을 중심으로 논의가 이뤄지고 있습니다. 내부자 매도는 매수보다 크게 앞서고 있으며, 기관 투자자들은 엇갈린 활동을 보이고 있고 애널리스트들은 MCK에 대해 높은 목표주가를 제시했습니다.
Vectus Biosystems Limited는 선도 후보물질 VB0004(특발성 폐섬유증을 표적)를 위한 FDA 제출 절차를 지원하기 위해 미국 규제 대리인으로 Cardinal Health Regulatory Services를 지정했습니다. 이번 전략적 파트너십은 희귀의약품 지정(Orphan Drug Designation)과 IND(임상시험용 신약) 신청을 포함해 미국에서 명확한 규제 경로를 확립하는 것을 목표로 합니다. 투자자들은 해당 회사의 향후 개발과 시장 잠재력에 있어 특히 VB0004와 관련해 규제 진행 상황을 면밀히 모니터링할 것입니다. VB0004는 유리한 안전성 프로파일로 Phase Ia 임상 연구를 완료했습니다.
카디널 헬스의 주가는 미국의 주요 헬스케어 의약품 및 의료용품 유통업체로서 다각화된 역할을 수행하는 덕분에 안정적으로 유지되고 있습니다. 반복적인 유통 물량과 덜 경기순환적인 헬스케어 수요에 의해 뒷받침되는 회사의 방어적(디펜시브) 특성은 헬스케어 공급망에 대한 노출을 원하는 투자자들에게 매력적으로 작용합니다. 이 회사의 비즈니스 모델은 규모, 운영 효율성, 가격 및 규제 리스크 같은 다양한 요인의 관리가 성과를 내는 한편, 고령화 같은 장기적인 헬스케어 트렌드의 혜택도 누립니다.
카디널 헬스의 주가는 공급망 전반에 걸친 폭넓은 도달력을 갖춘 미국의 헬스케어 유통업체로서의 중대한 역할 덕분에 안정적으로 유지되고 있습니다. 의료 및 제약 제품을 이동시키는 데 초점을 둔 회사의 비즈니스 모델은 헬스케어 수요와 트렌드에 대한 직접적인 연결고리를 제공하며, 이를 통해 방어형 투자로 자리합니다. 또한 대규모 운영은 물류와 컴플라이언스 비용을 광범위한 네트워크에 분산함으로써 구조적인 이점을 제공해, 고성장 기업이라기보다 성숙한 헬스케어 물류 기업으로 포지셔닝됩니다.
카디널 헬스의 주가는 유통 중심 비즈니스 모델 덕분에 안정적으로 유지되고 있으며, 북미에서 광범위한 의약품 및 의료용품 유통 네트워크가 이를 뒷받침합니다. 회사는 저마진 도매를 특수 제약 서비스와 의료-수술용 제품의 고부가 가치와 균형 있게 결합해 다양한 매출원(수익원을) 제공합니다. 투자자들은 회사의 효율적인 운영 관리, 현금흐름 창출 능력, 그리고 헬스케어 트렌드와 규제 환경에 적응하는 역량에 주목하고 있습니다.
카디널 헬스(CAH)는 뉴욕증권거래소(NYSE) 개장 전인 8월 11일에 2026 회계연도 4분기 및 연간 재무 실적을 발표하겠다고 밝혔습니다. 회사는 이러한 결과를 논의하기 위해 동부시간 오전 8시 30분에 웹캐스트를 진행할 계획이며, 해당 내용은 회사의 투자자 관계(Investor Relations) 페이지에서 확인할 수 있습니다. 웹캐스트 다시보기와 프레젠테이션 슬라이드는 12개월간 제공됩니다.
Cardinal Health, a major player in pharmaceutical distribution, is experiencing strong growth. This momentum is attributed to favorable prescription trends, strategic investments in specialty pharmaceuticals, and the rising impact of GLP-1 drugs. The company, alongside Cencora and McKesson, forms an oligopoly that distributes over 90% of the US pharmaceutical market.
Cencora, a key player in the pharmaceutical wholesale and distribution market, is facing pricing headwinds and industry trends that are projected to impact its 2026 sales figures. Despite a recent guidance cut and stock selloff, the company's fundamental business strategy and outlook are described as strong, maintaining its position as one of the top three domestic wholesalers. The article suggests that Cencora, along with Cardinal Health and McKesson, forms an oligopoly supplying over 90% of the US market.
McKesson, a major pharmaceutical wholesaler, benefits from its leadership in oncology and strong free cash flow, contributing to its durable fundamentals. The company, along with Cardinal Health and Cencora, forms an oligopoly that distributes over 90% of the U.S. pharmaceutical market. This report highlights McKesson's strategic position and financial strength as key drivers of its performance.
Cardinal Health's recent removal from several Russell indices, while seemingly concerning, is more a technical reclassification due to its significant share price appreciation rather than a reflection of weakening fundamentals. The company continues to show strong performance, particularly in its Specialty Healthcare Platform and other high-growth businesses, with analysts raising price targets and positive outlooks for future earnings. Despite competitive pressures and regulatory risks, its long-term growth drivers remain robust, suggesting existing investors may hold the stock.
Shares of Cardinal Health Inc. (CAH) fell by 1.43% on Thursday, closing at $233.77. This underperformance occurred despite a generally positive trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both seeing gains. This marks the second consecutive day of losses for Cardinal Health Inc. stock.
Cardinal Health (NYSE: CAH) announced it will release its fourth-quarter and year-end financial results for fiscal year 2026 on August 11, prior to the New York Stock Exchange opening. The company will host a webcast discussing these results at 8:30 a.m. Eastern time, accessible via its Investor Relations page. Presentation slides and a webcast replay will be available for 12 months.
Cardinal Health (NYSE: CAH) will release its fourth-quarter and full-year fiscal 2026 financial results on August 11, 2026, before NYSE trading opens. A webcast discussion of these results will begin at 8:30 a.m. Eastern, with slides and a replay available on the Investor Relations page for 12 months. This announcement follows a pattern of previous earnings-date notices, which historically have been followed by small positive stock moves.
Cardinal Health (NYSE: CAH) announced it will release its fourth-quarter and year-end financial results for fiscal year 2026 on August 11, before the New York Stock Exchange opens. The company will host a webcast at 8:30 a.m. Eastern to discuss these results, accessible via its Investor Relations page, where slides and a replay will also be available for 12 months. Cardinal Health is a major distributor of healthcare products and services, including pharmaceuticals, medical supplies, and data solutions.
Cardinal Health (CAH) experienced a market decline, falling 1.07% against the S&P 500's 0.28% loss. Despite this, the stock has shown a 12.72% gain over the past month, outperforming both the Medical sector and the S&P 500. Investors are anticipating a 15.87% EPS growth and 9.06% revenue increase in the upcoming earnings report, with the company currently holding a Zacks Rank #3 (Hold).
Cardinal Health Inc. (CAH) stock declined by 1.07% on Wednesday, closing at $237.15, during a generally poor trading session for the stock market. The S&P 500 Index fell 0.28% and the Dow Jones Industrial Average fell 1.09%. Cardinal Health Inc. finished 2.49% below its 52-week high of $243.21, which was reached the previous day.
Cardinal Health Inc., a major healthcare distributor and services provider, continues to refine its business around pharmaceutical and medical product distribution. The company is an S&P 500 component, making its performance closely watched by investors as an indicator of broader US healthcare trends. Its operations include pharmaceutical distribution and medical products, with a focus on logistics and supply chain management for hospitals, pharmacies, and other care providers.
McKesson Corporation recently experienced executive changes, with Ramesh Srinivasan becoming the new Chief Strategy Officer, and the company's inclusion in multiple Russell 1000 Defensive indexes. These developments, along with its existing strengths in specialty and oncology distribution, are reframing McKesson's investment narrative as a core healthcare distributor. The article suggests this combination of leadership transition and defensive benchmark inclusion underscores McKesson's evolving corporate direction and its potential as a resilient investment amidst regulatory pressures.
The Cardinal Health Kangaroo OMNI Enteral Feeding Pump is presented as a crucial device in US hospitals and long-term care facilities, designed to improve nutrition delivery with its connected, multi-feed system. It supports continuous or intermittent tube feeds for adult and pediatric patients and integrates formula, water, and medication delivery through a single platform. This product contributes significantly to Cardinal Health's recurring revenue stream through the sale of disposable feeding sets and service contracts.
Cardinal Health (CAH) was recently removed from several Russell "defensive" indices despite reporting strong quarterly revenue of US$60.94 billion and net profit of US$399 million. This reclassification occurs amidst reaffirmed positive analyst sentiment and commentary from figures like Jim Cramer, highlighting a potential disconnect between index categorization and the company's solid financial performance. Investors are encouraged to consider the company's core earnings drivers, future revenue and earnings projections, and the potential impact of regulatory scrutiny as they assess their investment narrative.
Evercore ISI has increased its price target for Cardinal Health (CAH) to $265, up from the previous $240. The adjustment reflects an updated valuation for the company.
Cardinal Health (CAH) is a key U.S. healthcare distributor that maintains a steady position as investors await a new company-specific catalyst. The Ohio-based company's scale in pharmaceuticals and medical products, along with its recurring supply flows and execution, are central to its investment case. The article highlights Cardinal Health's role in the U.S. healthcare supply chain and its exposure to prescription volumes and provider purchasing patterns.
Cardinal Health (CAH) stock has reached an all-time high of $241.86, displaying a significant 46.4% total return over the past year. Despite trading near its 52-week high, InvestingPro analysis suggests the stock remains undervalued, highlighting its strong market position and growth trajectory. The company also recently reported Q3 fiscal 2026 earnings, increased its quarterly dividend, and saw notable options trading activity.
This article argues that Cardinal Health should be viewed as a scaled healthcare-services platform with specialty and technology-enabled growth areas, rather than just a low-margin drug distributor. It highlights the company's Navista Oncology Network and radiopharmaceutical infrastructure as key differentiators. Investors are advised to focus on specialty growth metrics, Medical segment margin recovery, and capital allocation for a comprehensive valuation.
The Nuveen ESG Mid-Cap Value ETF (NUMV), launched in 2016, offers broad exposure to the Style Box - Mid Cap Value category, amassing over $439.18 million. It tracks the TIAA ESG USA Mid-Cap Value Index with an expense ratio of 0.31%. The ETF has shown strong performance, with a 12.76% return and a 19.89% year-to-date increase as of July 6, 2026, primarily allocated to Financials, Industrials, and Information Technology sectors.
Cardinal Health Inc. is leveraging its strong position in pharmaceutical and medical product distribution to meet evolving healthcare demands in the U.S. The company acts as a vital link between manufacturers and providers, benefiting from long-term trends like an aging population and increasing chronic diseases. Its operations involve extensive logistics, inventory management, and a broad product portfolio, ensuring reliable supply and supporting cost efficiencies for healthcare providers.
Cardinal Health Inc. is a leading distributor of pharmaceuticals and medical products in the U.S., playing a crucial role in the healthcare supply chain. Investors are focusing on how the company manages distribution growth, maintains margin stability amidst generic drug price fluctuations, and expands its healthcare service offerings. Its business is influenced by prescription drug volumes, generic pricing trends, and U.S. healthcare policies and regulations.
The article highlights the Cardinal Health Kangaroo Joey Enteral Feeding Pump as a foundational product in U.S. hospitals and home care, valued for its reliability, compact design, and ease of use. It details the pump's features, clinical utility, and role in Cardinal Health's medical segment revenue, emphasizing its "longseller" status due to consistent performance and integration into healthcare workflows. The piece also touches on regulatory compliance, competitive landscape, and the pump's financial significance for Cardinal Health.
Cencora (COR) is approaching its fiscal third-quarter earnings release on August 5, 2026, with current analysis suggesting it might be undervalued by 15.4%. The company's stock has shown strong long-term performance, and its investments in digital infrastructure are expected to drive higher margins and operating income. However, potential risks include increased regulatory scrutiny on drug pricing and heightened competition in specialty distribution.
Cardinal Health (CAH) has been removed from several Russell indices, prompting a review of its valuation. Despite strong share price momentum and being considered modestly undervalued by one narrative ($245.27 fair value), its high P/E ratio of 36x, compared to industry averages, suggests potential valuation risk. Investors are encouraged to conduct their own analysis given these mixed signals.
Jim Cramer expressed confidence in Cardinal Health (NYSE: CAH), recommending it to investors and stating that the stock deserves to trade higher despite a recent rotation out of healthcare. He highlighted the company's strong performance in a recent quarter. Cardinal Health supplies branded and generic medicines, and medical products.
Jim Cramer highlighted Cardinal Health (NYSE: CAH) as a strong stock that deserves to trade higher, despite being obscured by a recent healthcare sector rotation. He emphasized the company's "great quarter" and its position as a "real stalwart." Cramer also mentioned an earlier implosion of the stock that concerned him, but still believes in its potential going forward.
Jim Cramer expressed confidence in Cardinal Health (NYSE: CAH), recommending it among healthcare stocks that deserve to trade higher. He highlighted its strong performance, despite a recent market rotation out of healthcare, and noted that it is held in his Trust. Cramer believes the stock is a "stalwart" and has further upside potential.
Cardinal Health received a "Buy" rating due to its strong adjusted EPS growth of 35% in Q3FY26, defensive business model, and strategic expansion into specialty healthcare. Despite revenue growth of 11%, GAAP earnings were affected by higher costs. The company's premium valuation and future gains are contingent on maintaining margin improvements and managing risks like opioid litigation.
Cardinal Health (CAH) has been removed from several Russell indices, prompting investors to re-evaluate the stock. Despite a strong share price performance and analysts' valuation indicating it's slightly undervalued, its P/E ratio suggests a higher valuation risk compared to the industry and peers. The article discusses whether its current price reflects demanding future expectations.
Cardinal Health (CAH) was removed from several Russell indices following strong share price performance, leading investors to re-evaluate the stock. While Simply Wall St's narrative suggests it's slightly undervalued at $245.27, its P/E ratio of 36x is higher than the industry average, signaling potential valuation risk. Investors are encouraged to assess the full picture of the company's rewards and risks.
This article provides the latest SEC filings and comprehensive financial data for McKesson Corp (MCK). It includes current stock performance metrics, valuation ratios, dividend information, and insider and institutional ownership percentages, alongside various profitability and efficiency ratios.
This article provides financial data for Cardinal Health, Inc. (NYSE: CAH), specifically focusing on its enterprise value to revenue forward. It appears to be a financial snapshot from TradingView, including market information and links to various financial tools and community features.
The article provides the enterprise value to revenue forward for Cardinal Health, Inc. (MIL:1CAH). It appears to be a financial data point from TradingView, offering a quick snapshot of a valuation metric for the company.
The average 12-month price target for Cardinal Health, Inc. (CAH) stock has increased to $248.27 from $246.93, based on estimates from 15 analysts. This updated target suggests a potential 4% upside from the July 1 closing price. The consensus rating for CAH remains a "Buy" from 21 analysts.
This article briefly mentions the "Price to sales forward" metric for Cardinal Health, Inc. (NYSE: CAH). The content appears to be a stub or preview from a financial data platform, providing basic company information and navigation links without detailed financial analysis.
AI models are split on Cardinal Health (CAH) due to differing weights given to its strong earnings and cash flow versus its balance sheet risk and technical weakness. One bullish model highlights exceptional earnings momentum and raised guidance, while a more cautious model emphasizes concerns about leverage and short-term technical signals. This divergence suggests that the investment case for CAH depends on an investor's comfort with risk and tolerance for volatility.
Cencora has introduced CubixxCT, an RFID-enabled, temperature-controlled inventory management system for hospital and specialty pharmacy cold chains in the US. This system automates the tracking of high-value biologic drugs and vaccines, improving compliance, reducing waste, and integrating into existing clinical workflows. It represents Cencora's strategic move into service-based revenue beyond commodity drug wholesaling.
Cardinal Health is starting the week with significant attention from analysts due to its role as a major U.S. healthcare distributor and its inclusion in the S&P 500. Analysts are particularly focused on its operating margin trends, cash generation, and capital returns, balancing pressures from generic drug prices with opportunities in specialty pharmaceuticals. The company's performance and consensus estimates are closely watched by investors, especially concerning its impact on ETF flows and index-tracking strategies.
The article describes the Kangaroo ePump Enteral Feeding Pump from Cardinal Health Inc., highlighting its features such as programmable low-noise feeding, automatic flushing, and detailed history logs for hospital and home care. It emphasizes the pump's user-friendly design for nursing staff, its safety features, and its position as a key product within Cardinal Health's medical portfolio. Despite minor user frustrations with button responsiveness and display, the ePump remains a reliable device for enteral nutrition.
Cardinal Health, Inc. (NYSE: CAH) has been removed from the Russell 1000 Growth-Defensive Index, as announced on June 29, 2026. This news follows several other recent updates for the company, including analyst ratings, funding announcements, and dividend declarations. The company specializes in the distribution of pharmaceutical and medical products.
This article summarizes a bullish thesis on McKesson Corporation (MCK), arguing that its recent stock decline presents an attractive buying opportunity. The thesis highlights McKesson's dominant position in pharmaceutical distribution, its asset-light business model generating significant cash flow, and its strategic shift towards higher-margin businesses. Despite a recent revenue miss, the company's core investment thesis remains intact, with conservative estimates suggesting 18% upside and more realistic scenarios pointing to 70% upside.
Cardinal Health Inc (US14149Y1082) begins the week with its next earnings date as the primary focus for investors. The company, which trades on the NYSE, is a key player in the U.S. health care distribution sector, providing pharmaceuticals and medical products. Its business model relies on volume, pricing discipline, and logistics efficiency in a broad market.
